Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with... Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomeg- aly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocytosis could develop and the management of these situations is not well established. We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation. Both drugs were administered outside clinical trials. At 48 weeks, a significant reduction in leucocyte and platelet counts was observed (p =0.02 and p = 0.04, respectively). Additionally, the spleen volume decreased from a median value of 10 cm below the left costal margin (range, 0–10) to 6 cm (range, 0–15). The rate of spleen response increased from 14% at the start of the combination to 45% after 48 weeks. The safety profile of the combination was consistent with that observed with ruxolitinib single agent. These data require further confirmation in large cohorts of patients prospectively assessed. . . . Keywords Myelofibrosis Ruxolitinib Hydroxyurea Efficacy Introduction by hyperleukocytosis and thrombocytosis [2]. Ruxolitinib (JAKAVI, Novartis; JAKAFI, Incyte Corporation) is the first- Myelofibrosis (MF) is the most aggressive among Philadelphia- in-class JAK1/2 inhibitor that has demonstrated efficacy in reduc- negative chronic myeloproliferative neoplasms (MPN) and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Loading next page...
 
/lp/springer-journals/efficacy-and-safety-of-ruxolitinib-and-hydroxyurea-combination-in-CiuVCkj0eQ

References (18)

Publisher
Springer Journals
Copyright
Copyright © 2019 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
DOI
10.1007/s00277-019-03727-6
Publisher site
See Article on Publisher Site

Abstract

Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomeg- aly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocytosis could develop and the management of these situations is not well established. We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation. Both drugs were administered outside clinical trials. At 48 weeks, a significant reduction in leucocyte and platelet counts was observed (p =0.02 and p = 0.04, respectively). Additionally, the spleen volume decreased from a median value of 10 cm below the left costal margin (range, 0–10) to 6 cm (range, 0–15). The rate of spleen response increased from 14% at the start of the combination to 45% after 48 weeks. The safety profile of the combination was consistent with that observed with ruxolitinib single agent. These data require further confirmation in large cohorts of patients prospectively assessed. . . . Keywords Myelofibrosis Ruxolitinib Hydroxyurea Efficacy Introduction by hyperleukocytosis and thrombocytosis [2]. Ruxolitinib (JAKAVI, Novartis; JAKAFI, Incyte Corporation) is the first- Myelofibrosis (MF) is the most aggressive among Philadelphia- in-class JAK1/2 inhibitor that has demonstrated efficacy in reduc- negative chronic myeloproliferative neoplasms (MPN) and

Journal

Annals of HematologySpringer Journals

Published: Jun 14, 2019

There are no references for this article.